Munir, T., Varghese, A. M., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, P. J. G., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Hockaday, A., Cairns, D. A., Jackson, S., …Hillmen, P. (2024, December). IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study. Presented at 66th American Society of Haematology Annual Meeting, San Diego